- Endocrinology
- Metabolic Syndrome
- Pharmacology
- +۷ مورد دیگر
Timo Mueller is a Director at the Institute for Diabetes and Obesity and a W3 Professor at the Walther-Straub Institute for Pharmacology and Toxicology , Ludwig-Maximilians-University Munich (LMU). His work bridges endocrinology , molecular pharmacology , and metabolic disorders to develop personalized preventive and therapeutic strategies for obesity and diabetes. Education: Animal Physiology, Philipps-University Marburg, Germany Ph.D. in Child and Adolescent Psychiatry, University of Duisburg-Essen, Germany (2009) His research on gut hormone-based therapies (e.g., GLP-1, GIP, glucagon) has revolutionized obesity and diabetes treatment. Key contributions include: Establishing GLP-1/GIP co-agonists for weight loss Refuting the role of alternatively activated macrophages in thermogenesis Decoding GIP receptor signaling in the central nervous system Engineering liver-targeted T3 delivery via glucagon His >190 publications span Cell , Nature , and Cell Metabolism . Awards include the Minkowski Award (2023), ERC Consolidator Grant (2022), and Werner-Creutzfeldt Prize (2023). Scientific Awards: Minkowski Award (EASD) - 2023 Werner-Creutzfeldt Prize (DDG) - 2023 Galenus-von-Pergamon Award - 2022 ERC Consolidator Grant (TRUSTED) - 2022 DZD Diabetes Award - 2015 As Head of the Division of Molecular Pharmacology at Helmholtz Munich since 2011 and Director since 2023 , Mueller leads an international team exploring central and peripheral metabolic signaling to combat obesity, diabetes, and comorbidities. Current projects focus on GIP receptor mechanisms and novel hormone-based therapies .








